Podcasts about Novo Nordisk

David Faber, Sara Eisen and Michael Santoli led off the show with what's next for regional banks one day after credit concerns sparked a sell-off in that group. Breaking news from Sara: Apple announced a five-year deal for U.S. streaming rights to Formula 1 races. Shares of Novo Nordisk and Eli Lilly down sharply on President Trump's push to lower prices of Novo's blockbuster weight-loss drug Ozempic. Also in focus: Market reaction to Trump's comments on China tariffs, American Express' earnings beat, what Oracle's new CEOs told David, gold rally takes a breather, CoreWeave-Core Scientific deal latest.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

n the News.. COVID-19 & T1D, Ozempic Pill Progress, Faster Insulin, “Beyond Misconceptions,” and More It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new study looks at the link between COVID-19 and very young children, Lilly moves ahead with their Ozempic oral pill, ultra-rapid insulin clears another hurdle, Beyond Type 1 launches a new campaign and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX https://www.scientificamerican.com/article/advances-in-type-1-diabetes-science-and-tech/ This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. XX More evidence linking COVID 19 to type 1 diabetes.. but still exactly why is a mystery. During the COVID-19 pandemic, there was an unexpected increase in the number of cases of type 1 diabetes in Sweden, particularly among children under 5 and young adult men. The infection accelerated the onset of diabetes among children between the ages of 5 and 9. The researchers looked at data from a 17-year period on the incidence of type 1 diabetes among all people under the age of 30 in Sweden. In addition, they compared the risk of developing diabetes among 720,000 individuals with positive COVID-19 tests against a control group of 3.5 million people. The findings are published in the journal Diabetologia. The number of diabetes cases increased by 12% in 2021 and 9% in 2022 compared with previous years. In 2023, the number of cases was back to a normal level. Despite this, the researchers cannot distinguish a clear connection between COVID-19 infection and diabetes, except for children between 5 and 9 years old. They had an increased risk of type 1 diabetes about one month after a COVID-19 infection even though their total risk did not increase. "However, it's clear that the COVID-19 vaccine can be ruled out as a cause of the increase in diabetes cases. The recommendation for the age group where we saw the strongest increase was not to get vaccinated. In addition, other studies on adults have shown that vaccination reduces the risk of developing type 1 diabetes after a COVID infection." https://medicalxpress.com/news/2025-10-diabetes-young-people-pandemic.html XX A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious and common complication of the condition, has shown promising results in a University of Bristol study. Findings from this new study, published in Molecular Therapy, demonstrated a 64% reduction in a damage indicator for kidney disease, paving the way for a potential new treatment. The study, explored the potential of delivering a protein called VEGF-C directly into kidney cells. Previous studies have shown VEGFC could protect against kidney disease as it helps keep blood vessels in the kidney filter healthy, repairing early signs of diabetes-related kidney damage. https://medicalxpress.com/news/2025-10-gene-therapy-kidney-disease-diabetes.html XX The FDA has agreed to consider Afrezza inhaled insulin for children and teens. The company said in August that it submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population and it's been assigned a decision deadline date of the end of May, 2026. Afrezza first recieved FDA approval for adults (age 18 and up) in June 2014 https://www.drugdeliverybusiness.com/fda-accepts-application-mannkind-inhaled-insulin-kids/ Update on inhaled insulin for kids.. in the open-label, randomized, phase 3 INHALE-1 clinical trial Afrezza demonstrated safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes (T1D and demonstrates comparable glycemic control to injected rapid-acting insulin. The INHALE-1 clinical trial assessed the safety and efficacy of Afrezza among children and adolescents with T1D, including a total of 230 patients aged 4 to 17 years. Researchers used basal injected insulin and randomly assigned inhaled insulin or rapid-acting analogue for meals, evaluating the change in hemoglobin A1c levels at 26 weeks. After completing 26 weeks of randomly assigned treatment with either Afrezza or rapid-acting insulin injections combined with basal insulin, participants continued receiving the inhaled insulin until week 52 for an extension phase to evaluate the safety and effectiveness of Afrezza with continued use.1,2 https://www.pharmacytimes.com/view/inhaled-insulin-demonstrates-comparable-safety-lung-function-and-efficacy-to-injectable-insulin-in-type-1-diabetes XX Eli Lilly released the results of two new Phase 3 trials of an experimental GLP-1 pill that the company says could become a “foundational treatment” for type 2 diabetes. The Indianapolis-based drugmaker plans to submit global regulatory applications for orforglipron in the treatment of type 2 diabetes next year. The company said it will seek approval of the drug as an obesity medication by the end of 2025. Lilly is trying to build on the success of its Mounjaro/Zepbound franchise by offering patients a pill instead of an injection. But the company is trailing behind rival Novo Nordisk in developing an oral alternative, and data released so far has raised some skepticism among investors. A study released in August showed that orforglipron could help patients lose an average of about 12% of their body weight. Wall Street had been expecting more; Lilly's injectable drug Zepbound produced weight loss of as much as 21%, and Novo Nordisk has achieved 15% weight loss percentages for both oral and injectable versions of its Wegovy medication.   https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins   XX XX UF Health Cancer Center researchers have found a surprising culprit behind common health problems such as obesity, diabetes and fatty liver disease: silent genetic glitches in the blood system that occur naturally as people age. The findings, published in the Journal of Clinical Investigation, mean that in the future, simple blood tests could be developed to identify people most at risk early on, helping prevent chronic illnesses and cancer through strategies like diet or lifestyle changes. As people age, stem cells in the bone marrow that produce blood cells gradually accumulate mutations in their DNA. Most mutations don't cause any issues, but sometimes blood stem cells with a mutation can start crowding out their peers. Called clonal hematopoiesis, this condition affects about 10% of older people and is associated with an increased risk of blood cancers like leukemia. It's also linked to a higher risk of obesity and diabetes. But the prevailing thinking was that obesity and related conditions promoted blood cell changes, not the other way around. The new study reverses that. The implications could be far-reaching, particularly as obesity has now overtaken smoking as the most significant and preventable risk factor for cancer. The team is studying how the mutations drive disease. Next, they plan to test how drugs like those commonly used to treat diabetes and new popular weight loss drugs might help reverse or prevent diseases caused by blood cell changes. https://medicalxpress.com/news/2025-10-hidden-blood-mutations-obesity-diabetes.html XX A new ultra rapid insulin continues to move forward. A phase 3 clinical trial of BioChaperone Lispro (liss-pro) conducted in China found it safe and effective compared with Humalog along with a significant reduction of the rise of blood glucose after a test meal.     These results complete and confirm the positive outcomes previously obtained with THDB0206 injection in people with Type 2 Diabetes It combines Adocia's proprietary BioChaperone® technology with insulin lispro, the active ingredient in the standard of care, Humalog® (Eli Lilly).   This innovative formulation acts significantly faster https://pharmatimes.com/news/ultra-rapid-insulin-shows-promise-in-phase-3-trial-for-type-1-diabetes/   Poor blood sugar control in adolescent patients with type 1 diabetes (T1D) may be associated with a higher risk of neuropathy in adulthood, according to recent research from the University of Michigan.1 The study included children diagnosed with T1D between 1990-1992 who were recruited into the Cognition and Longitudinal Assessment of Risk Factors over 30 Years cohort study in Australia. Investigators collected HbA1c from medical records, and microvascular complications were assessed through self-reports, clinical screenings, retinal photographs, and urinary albumin-creatinine testing.3   A total of 30 children were recruited from the original cohort with a mean diagnosis age of 2.9 years. After an average of 29.7 years (standard deviation [SD]: 3.9 years), 33% of participants (n = 13) developed neuropathy, 63% (n = 19) developed diabetes-related eye disease, and 10% (n = 3) developed neuropathy.3 Mean HbA1c estimates during adolescence (9% [74.9 mmol/mol]; 95% CI, 8.6-9.3 [70.5-78.1]) were substantially higher than childhood (8.2% [66.1 mmol/mol]; 95% CI, 7.8-8.5 [61.7-69.4]; P

US equity futures lower with S&P down (1.4%). European equity markets are sharply lower, follows firmer close on Thursday. Asian equity markets were weaker. Bonds strengthen, tracking big move in treasuries which sees US 10-year at 3.95%. Dollar is weaker. Oil down. Gold extends to new record high. Industrial metals mixed. Bitcoin lower. Markets have been keying off renewed turbulence in US regional banking space after KRX fell 6% to four-month low amid regional-bank credit concerns, which added to concerns over souring loans following collapse of subprime auto lender Tricolor and autoparts maker First Brands. Developments drew attention to JP Morgan CEO Jamie Dimon's warning about potential for more revelations. Press also highlighted concerns stemming from riskier credit as big investors dial back exposure.Companies Mentioned: CME Group, Eli Lilly, Novo Nordisk

Welcome back to the EUCVC Summit Talks, where we bring you candid conversations with Europe's leading founders, corporate leaders, and investors shaping the future of venture collaboration.In this episode, Anne C. Fleischer, Global VP of Consumer Engagement and New Business Models at Novo Nordisk, joins Henrijette Richter, Managing Partner at Sofinnova Partners, for a conversation on the future of health innovation.Together they explore how corporates and VCs are driving the next wave of digital health, the role of AI in transforming patient care, and what it takes to turn breakthrough science into scalable business models.

Artificial Intelligence is transforming corporate learning, but not every organization is doing it in ways that employees actually trust. In this episode of Workplace Stories, we talk with Peter Manniche Riber, Digital Learning & AI Leader, about how his team built AI-powered learning tools that employees truly believe in.From creating the “Dilemma Coach” and “IDP Coach” to redefining personalization and data privacy, Peter demonstrates what happens when innovation is combined with practicality, and why sometimes the smartest move is to build, rather than buy.You will want to hear this episode if you are interested in...[00:00] Why “believability” is the key to AI adoption.[04:50] How Novo Nordisk's “Dilemma Coach” and “IDP Coach” came to life.[09:00] Why less data, and the right data, creates better personalization.[17:00] Balancing privacy, ethics, and personalization in AI learning.[25:30] Working with works councils and data regulators early.[33:00] Scaling learning equity and access across global teams.[39:40] What AI means for strategic workforce planning.[41:30] Peter's advice for L&D leaders ready to experiment with AI.The Power of “Believability” in AI LearningAt Novo Nordisk, Peter's team coined a simple but powerful concept, believability. It means people will only engage with AI tools if they recognize themselves and their context in the experience. Through hundreds of user tests, they found that when an AI response feels personal and relevant, adoption skyrockets.Rather than hoarding corporate data, they ask employees directly about their goals, challenges, and career aspirations. This approach not only keeps data secure but also ensures every interaction feels real, human, and trustworthy.Why Novo Nordisk Built Its Own AI ToolsWhen it came to designing learning applications, Peter's team decided to build rather than buy. The reason? Control, context, and compliance. Off-the-shelf tools couldn't meet Novo Nordisk's strict privacy standards or reflect its unique leadership culture. By developing internally, the team could train AI on company-specific frameworks, design intuitive UX guardrails, and maintain full ownership of their data, while spending less than a handful of traditional e-learning modules would cost.Redefining Data and TrustInstead of scraping internal systems, Peter's philosophy is simple: ask people. Employees willingly provide fresh, accurate context when they understand how it's used. Transparency and consent are baked into the process, with large-font screens explaining how data is handled and why it matters.The result? Nearly 90% of employees feel completely safe using these tools, a remarkable trust level for AI-driven systems inside a regulated, global company.The Future of L&D and AI ExperimentationPeter's message to learning leaders: stop waiting for perfection and start experimenting. You don't need a massive budget or a team of data scientists to create meaningful AI applications. What you need is curiosity, clear hypotheses, and the courage to learn by doing.AI won't replace thoughtful design or human judgment, but it can unlock a new era of personalized, scalable, and believable learning.Resources & People MentionedNovo NordiskConnect with Peter Manniche RiberLinkedIn: Peter Manniche RiberConnect With Red Thread ResearchWebsite: Red Thread ResearchOn LinkedInOn FacebookOn TwitterSubscribe to WORKPLACE STORIES

Why is now the right time to focus on weight? On My Weight Live, Dr. Tiffany Lowe Clayton shares why taking action today can make all the difference for your health.This podcast was sponsored by Novo Nordisk Canada. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.The medical information in My Weight - What to Know's content is provided as an information resource only. The content is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice or treatment.All content of this channel is owned by What To Know, LLC. and is protected by worldwide copyright laws. You may download content only for your personal use (i.e., for non-commercial purposes) but no modification or further reproduction of the content is permitted. The content may otherwise not be copied or used in any way.My Weight - What to Know ©️ 2025

Biotech's fourth quarter began with a familiar feeling, with indicators pointing toward an improving public market even as political and regulatory uncertainty has buysiders reluctant to say industry has returned to sustainable growth. On the latest BioCentury This Week podcast, BioCentury's analysts assess the state of biotech's public markets. The analysts discuss the Senate's move to limit access to Chinese CDMOs, the latest developments in the White House's “most favored nation” drug pricing negotiations, and the U.K.'s attempt to win over pharma companies via adjusting thresholds at NICE. Finally, they analyze a pair of billion-dollar-plus M&A deals: the $4.7 billion deal by Novo Nordisk to acquire liver disease company Akero and the $1.5 billion takeout of in vivo cell therapy company Orbital by Bristol Myers. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657260#biotech #biopharma #pharma #lifescience #drugpricing #MFN00:01  Sponsor Message: Evotec02:12  4Q Markets Preview13:25  China CDMOs24:35  Drug Pricing Deals NHS31:22  Drug Pricing Deals M&ATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Emotional scenes in Tel Aviv as families count down the hours until Monday's deadline to release the hostages. Near Chicago, more clashes between protestors and police outside an ICE facility. And fans remember Diane Keaton, revered for her comic timing and legendary role as Annie Hall. In Kalundborg, Denmark, Novo Nordisk employs the equivalent of a third of the population. Learn about how that's impacted the city, in the latest episode of On Assignment here. Sign up for the Reuters Econ World newsletter here.  Listen to the Reuters Econ World podcast here. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices.  You may also visit megaphone.fm/adchoices to opt out of targeted advertising.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

When it comes to the topic of drug discovery and development, scientists are busy furrowing their lab-goggled brows trying to understand what's real and what's hype when it comes to the power and potential of AI. This *Resonance Test* conversation perfectly dramatizes the situation. In this episode, Emma Eng, VP of Global Data & AI, Development at Novo Nordisk, and Chris Waller, EPAM's VP of Scientific Informatics Consulting and Chief Scientist in Life Sciences, provide a candid view of drug development in the AI era. “We're standing on a revolution,” says Eng, reminding us that “we've done it so many other times” with the birth of the computer and the birth of the internet. It's prudent, she cautions, not to rush to judgement guided by either zealots or skeptics. Waller says, of the articles about AI and leadership in *Harvard Business Review,* one could do “a search and replace ‘AI' with any other technological change that's happened in the last 30 years. It's the same kind of trend and processes and characteristics that you need in your leadership to implement the technology appropriately to get the outcomes that you're looking for.” Which means, for pharma, much uncertainty and much experimentation. “I think experimentation is good,” says Eng, who then adds that we need to always keep track of what is it that we're experimenting on. She says that the word “experimentation” can “sound very fluid” but in fact, “It's a very structured process. You set up some very clear objectives and you either prove or don't prove those objectives.” Waller references the various revolutions (throughput screening, combinational chemistry, data, and analytics revolutions) that pharma has seen and says: “We've all held out hope for each and every one of these revolutions that the drug discovery process is going to be shrunk by 50% and cost half as much. And every time we turn around, it's still 12 to 15 years, $1.5 to $2 billion.” Will AI make the big difference, finally? “Maybe we need to be revolutionized as an industry,” she says. “It can be hard to make much of a difference as long as there are few big players.” Just a few big players, she says, is “the nature of pharma.” Of course, our scientists are measured in their assessments about industry change. After all, as Waller says, the systems involved—the human body, the regulatory environment, the commercial ecosystems—are all “super-complicated.” Eng notes that an important side-effect around the AI hype is corporate interest in data. “Now it's much easier to put that topic on the table saying, ‘If you want to do AI, you need to take care of your data and you need to treat it like an asset.'” Listen on as they test topics such as regional and regulatory challenges in AI adoption, change management, and future tech and long-term impact (watch out for quantum, everyone!). In the end, Eng returns to the idea of revolutions. “You think you want so much change in the beginning which you don't get because it takes time,” says Eng. This makes us underestimate what will happen later. Having such a farseeing mindset is significant, she says, because “these technology shifts will have a large impact on the long term.” Host: Alison Kotin Engineer: Kyp Pilalas Producer: Ken Gordon

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Rätselraten um Tesla, eine Mega-Kapitalerhöhung bei Orsted und Dividendenglück bei Hannover Rück. Außerdem geht es um BNP Paribas, Crédit Agricole, Société Générale, Munich Re, Talanx, Redcare Pharmacy, Figma, HubSpot, Salesforce, Expedia Group, TripAdvisor, Mattel, PlugPower, AMD, Oracle, Nvidia, Amazon, Alphabet, Microsoft, Broadcom, Novo Nordisk, Nvidia, Rheinmetall, Renk, Palantir, Allianz, ASML Holding, Apple, Deutsche Telekom, Droneshield, iShares Core MSCI World (WKN: A0RPWH), der Vanguard FTSE All-World (WKN: A2PKXG), VanEck Morningstar Developed Markets Dividend Leaders (WKN: A2JAHJ), VanEck Defense (WKN: A3D9M1), WisdomTree Europe Defence (WKN A40Y9K), Xtrackers Artificial Intelligence & Big Data (WKN: A2N6LC) und iShares S&P 500 Information Technology (WKN A142N1).  Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Lars Petersen, President & Chief Executive Officer at FUJIFILM Biotechnologies.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lars, covering: The difficult decision to leave Novo Nordisk and make the jump from one great company to another in Genentech/Roche. How leaving a Biogen site led him to step away from big pharma after 25 years and transition to the CDMO side. How Fujifilm's culture of innovation, technology, quality, and people runs through the Biotechnologies division — and why empowerment and culture should never be compromised. Why the duplication of its CDMO sites globally, all running on the same kojoX platform, is truly differentiating. Why he believes the need to standardise, scale, and globalise drug production in a consistent, efficient, and traceable way is key to the future of the supply chain. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate.    Lars Petersen, CEO of FUJIFILM Biotechnologies, is recognized as a visionary leader in the life science sector, commanding a global contract development and manufacturing organization (CDMO) with nearly 5,000 employees spread across Denmark, UK, USA, and Japan.    Distinguished for his strategic vision and a "people first" philosophy, Lars has profoundly impacted the company and the industry. His leadership journey saw him rise from Chief Operational Officer & Senior Vice President at the Danish site, where he established an empowering culture, to CEO, promoting transparency across all operations. Since his global leadership appointment in June 2023, Lars has been instrumental in cultural transformation, integrating a "people first" approach across FUJIFILM Biotechnologies' global facilities regardless of geographical differences.   Prior to his appointment as CEO, Lars was responsible for the Global Large Scale Commercial operation including full profit and loss accountability as well as the responsibility for over $6.2 Billion global expansions both in Hillerød, Denmark, and Holly Springs, North Carolina, USA.   Previously, Lars has held leadership positions with Biogen, Genentech/Roche, Novo Nordisk, Novozymes and NNE, and he has successfully executed projects in Europe, China and the US.   Lars holds a master's degree from the Technical University of Denmark.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! 

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Gamechanger-Deal, Wall-Street-Rekorde trotz Shutdown und das fulminante Börsendebüt von Fermi. Außerdem geht es um Pfizer, Merck, Eli Lilly, Novo Nordisk, Vertex, Regeneron, Thermo Fisher, Repligen, Danaher, Boston Scientific, Abbott, Intuitive Surgical, Bayer, Merck, Salzgitter, Thyssenkrupp, Bitcoin, Solana, Ether, Sartorius, Palantir Technologies, Thales, L3Harris Technologies, RTX, Kratos Defense & Security Solutions, AeroVironment, DroneShield, Elbit Systems, Electro Optic Systems, Saab AB, Hensoldt, Mercury Systems, QinetiQ, Chemring Group, Cohort, Exail Technologies, Rocket Lab, Iridium Communications, BlackSky Technology, Electro Optic Systems, Leidos Holdings, CACI International, Parsons, Telos Corp, Leidos, SAIC, QinetiQ, Parsons VanEck Space Innovators ETF (WKN: A3DP9J), Invesco Defence Innovation ETF (WKN: A40J95), Global X Defence Tech ETF (WKN: A40E7A), Droneshield, Palantir, Red Cat Holdings. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die großen Verschiebungen im 3. Quartal, Trumps wirren Deal mit Pfizer und Wolfspeed, die wie Phoenix aus der Asche steigen. Außerdem geht es um Applovin, Western Digital Corp, Warner Bros, Seagate Technologies, Intel, Tesla, Charter Communications, Trade Desk, Lululemon, FactSheet, Molina Healthcare, Gartner, Commerzbank, Deutsche Bank, BMW, Airbus, Fresenius, Bayer, Deutsche Börse, Symrise, Beiersdorf, Lithium America, Berkshire Hathaway, Occidental Petroleum, Nike, Adidas, Puma, Electronic Arts, MoonLake Immunotherapeutics, Insmed Incorporated, Madrigal Pharmaceuticals, Krystal Biotech, Mineralys Therapeutics, Vera Therapeutics, Summit Therapeutics, TripAdvisor, Zoom Communications, Unity Software, Workiva, Trimble, Take-Two Interactive Software, Avepoint, Groupon, Magnolia Oil, Kinetik Holdings, Kosmos Energy, Parsons Corporation, Hexcel Corporation, Science Applications International, Kratos Defense & Security Solutions, Scout24, Brenntag, Hugo Boss, Nordex, Temenos, Avolta, Burberry, Remy Cointreau, Whitbread, Reckitt Benckiser, Amadeus IT Group, Moncler, Signify, Iveco Group, EDP Renovaveis, Solaria Energia, Novo Nordisk, Eli Lilly, Vanguard FTSE All-World ETF (WKN: A2PKXG). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Alex Natskovich is the Founder and CEO of MEV, LLC, a technology services firm that builds custom software and modernizes digital systems for life sciences, real estate, and pharma companies. With over 20 years in software engineering, he has led 200+ projects across diverse industries and specializes in distributed systems, cloud computing, and large-scale data processing. Under his leadership, MEV has delivered major projects for clients such as Cartier, Novo Nordisk, and Daiichi Sankyo. In this episode… Surviving economic chaos can forge an entrepreneurial spirit that thrives in uncertainty. What lessons can be drawn from growing up in a place where scarcity and improvisation are part of daily life, and how do those lessons translate into building successful teams and technology today? Alex Natskovich, a veteran software engineer and product leader, believes resilience and resourcefulness are the foundation of innovation. He shares how early hardships taught him to adapt quickly, think creatively, and focus on core values when hiring talent. From avoiding common product pitfalls, like untested assumptions and weak data privacy, to embracing AI tools such as GitHub Copilot and Fireflies for smarter development, his insights reveal how to build scalable, market-ready products. These experiences underscore the importance of aligning strategy, technology, and culture to win in competitive markets. In this episode of the Inspired Insider Podcast, Dr. Jeremy Weisz sits down with Alex Natskovich, Founder and CEO of MEV, to discuss how early-life resilience shaped his leadership in software development. He explores hiring based on core values over technical skills, lessons from guiding Hawaii Information Service's MLS platform overhaul, and the impact of AI on client expectations and product development.

Synopsis: When biotech meets bold partnerships, new models of innovation emerge. In this episode of the Biotech 2050 Podcast, host Rahul Chaturvedi welcomes Paul Biondi, Managing Partner at Flagship Pioneering, and Uli Stilz, Vice President, R&D External Innovation Partners at Novo Nordisk, to explore the power of co-creation. Together, they unpack how Flagship's pioneering medicines model and Novo's Bio Innovation Hub intersect to accelerate breakthroughs in obesity, diabetes, and cardiometabolic diseases. They share lessons on building trust, navigating crises, and structuring alliances that go beyond transactions into enduring innovation ecosystems. From human disease atlases to new frameworks for agile collaboration, this episode offers a rare behind-the-scenes look at how pharma and biotech can partner differently—turning complexity into transformative therapies. Biography: Paul Biondi is a Managing Partner at Flagship Pioneering, leading Flagship's product and partnering capabilities, including Pioneering Medicines, Partnering, and Pipeline and Product Innovation. In this role, Paul oversees Pioneering Medicines, Flagship's in-house drug discovery and development unit, as well as therapeutic partnering and business development efforts for the Flagship ecosystem, including driving broad institution-wide Innovation Supply Chain partnerships with biopharma companies to jointly conceive and create innovative products. Paul also works with Flagship company CEOs and their teams to achieve the best attainable value for each company, guiding them in their pipeline strategy, product concepts, R&D execution, and partnering approach. He serves on the boards of Flagship-founded companies, including Tessera Technologies (NASDAQ: TSRA) and Valo Health. Paul Biondi is Managing Partner at Flagship Pioneering, joining after 17 years at Bristol-Myers Squibb (BMS), where he served as SVP of Strategy & Business Development and held leadership roles in R&D. He previously spent nine years at Mercer Management Consulting. Paul earned his MBA from the Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College. Uli Stilz is Corporate Vice President, R&D External Innovation Partners, External & Exploratory Innovation (E2I) at Novo Nordisk., based in Boston. He leads a global R&D team that builds creative partnerships with biotech, venture capital, academia, and research hospitals to co-create next-generation therapeutics in cardiometabolic and rare diseases. Building on the success of the Novo Nordisk Bio Innovation Hub, Uli and the E2I team drive an externally anchored portfolio of collaborations that stimulate global innovation ecosystems and advance Novo Nordisk's pipeline. Uli Stilz earned his Master's in Organic Chemistry from ETH Zürich and a Ph.D. in Biochemistry from the Max-Planck-Institute of Biochemistry in Martinsried, followed by postdoctoral research at Caltech. He began his industry career at Hoechst AG and later Sanofi, where he became Associate VP of the Innovation Unit in the Diabetes Division. Over two decades, he contributed to more than 60 preclinical and clinical drug candidates in cardiometabolic, immunology, and oncology. From 2012–2014, he served as President of the European Federation for Medicinal Chemistry. In 2014, Uli joined Novo Nordisk in Copenhagen and in 2019 moved to Boston to establish and lead the Bio Innovation Hub, now the External & Exploratory Innovation (E2I) organization. He also serves as Adjunct Professor at the University of Frankfurt, sits on editorial and scientific advisory boards, and holds board roles at the Kendall Square Association and Gensaic, while advising the aMoon Fund.

Are you a night owl or a morning lark?For many of us the traditional working day just doesn't suit our circadian rhythms. We're called into a meeting or slumped over a desk at 8am but hyper focused as we're about to leave the office and head home. What if work took our biological clocks into account?In this episode I am joined by Camilla Kring, author of Chrono leadership. We talk about the costs of rigidity in work patterns, and what it takes to develop smarter, more flexible arrangements.Camilla's ideas are revolutionary; she talks about taking the bias away from the 5am club and creating better conditions in the workplace for all. Surely that is something we would all want to get behind.So, when do you perform at your best during the day?“Synchronise your work, family, and biological rhythms for real performance.” - CamillaYou'll hear about:·      How circadian rhythms dictate our natural sleep and wake cycles.·      Why understanding your chronotype can enhance productivity.·      The fact most people are not morning persons, yet workplaces favour early risers.·      How living out of sync with your internal clock can harm health.·      Flexibility in work hours can lead to higher productivity and well-being.·      Trust in employees being crucial for implementing flexible work schedules.·      Why synchronising work and family rhythms can improve life quality. More about Camilla:Camilla Kring, as the founder of Super Navigators, has dedicated the last 20 years to helping individuals navigate their lives and organisations create flexible and inclusive work cultures that accommodate different chronotypes and family structures. She has worked across Europe, China, Latin America and the Middle East with companies including Abbott, Medtronic, Roche and Novo Nordisk.Camilla's insights have been featured in the New York Times, the BBC and the Guardian. She is the author of six books and a TEDx speaker. She holds a Master of Science in Engineering and a PhD in work-life balance from the Technical University of Denmark (DTU). Resources:• Profile: https://www.camillakring.com/about-camilla/ • Book - Chronoleadership: https://www.camillakring.com/books/ • Supernavigators services: https://www.supernavigators.com/   My resources:Try my High-stakes meetings toolkit (https://bit.ly/43cnhnQ) Take my Becoming a Strategic Leader course (https://bit.ly/3KJYDTj)Sign up to my Every Day is a Strategy Day newsletter (http://bit.ly/36WRpri) for modern mindsets and practices to help you get ahead.Subscribe to my YouTube channel (http://bit.ly/3cFGk1k) where you can watch the conversation.For more details about me:●      Services (https://rb.gy/ahlcuy) to CEOs, entrepreneurs and professionals.●      About me (https://rb.gy/dvmg9n) - my background, experience and philosophy.●      Examples of my writing https://rb.gy/jlbdds)●      Follow me and engage with me on LinkedIn (https://bit.ly/2Z2PexP)●      Follow me and engage with me on Twitter (https://bit.ly/36XavNI)

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über das Allzeithoch beim Gold, schwere Zeiten für Novo Nordisk und einen Rekord-Deal bei Private Equity. Außerdem geht es um MoonLake Immunotherapeutics, Electronic Arts, Hensoldt, Renk, Rheinmetall, Heidelberg Materials, Intel, MP Materials, Lithium Americas, U.S. Steel, Nippon Steel, Nvidia, AMD, Apple und Rheinmetall. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Genmab køber hollandsk biotek­sel­skab for 51 mia. kr. Søstrene Grene slår rekord og øger milliardsalg med 31 pct. Novo Nordisk tilbyder ansatte degradering eller fyring. Obton stemmer ja til redningsplan. Konsor­tium køber Electronic Arts for over 50 mia. dollar. Netanyahu godkender Trumps 20-punkts fredsplan for Gaza. Vance advarer om at USA styrer mod regeringsnedlukning. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)  

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest breakthroughs and controversies surrounding Ozempic, its medical use, and its impact on everyday wellness.The big headline this month is the arrival of a new pill form of semaglutide, the main ingredient in Ozempic. According to The New England Journal of Medicine, people who took this daily pill lost almost 14 percent of their body weight over 64 weeks, compared to just 2 percent for those on a placebo. Fifty percent of the patients shed at least 15 percent of their weight, with nearly a third losing 20 percent or more. Novo Nordisk, the company that makes Ozempic, announced even stronger results for those who stuck to their treatment plan, with close to 17 percent average weight loss. This pill, pending approval, could be a game changer for people who prefer not to take injections.On the injectable front, clinical trials featured in The Lancet indicate that a higher 7.2 milligram weekly dose of semaglutide in adults without diabetes led to almost 19 percent average weight loss, higher than what's seen with lower doses. These numbers highlight ongoing efforts to increase the effectiveness of Ozempic for those struggling with obesity.Yet, it's crucial to balance these promising results with real-world insights. The Mayo Clinic and NYU Langone Health recently compared Ozempic's results to traditional weight loss surgery, like gastric bypass and sleeve gastrectomy. Their research revealed that surgery is five times more effective than GLP-1 drugs such as Ozempic, with surgical patients losing an average of 58 pounds after two years versus just 12 pounds for those on the drug for six months. Experts also noted that only 30 percent of patients stick with GLP-1 drugs for longer than a year, and real-world weight loss may be lower than trial results suggest. Surgery, however, isn't without its risks, including potential infections, blood clots, and hernias, and requires strict diet and lifestyle changes afterward.Turning to genetics, Cleveland Clinic research shows that the effectiveness of Ozempic may depend on your DNA. A specific variant in the Neurobeachin gene seems to make some people much more responsive to these medications, leading to 82 percent higher odds of substantial weight loss. This new insight could help doctors tailor treatments so patients get therapies most suited to their genetic profile.Lifestyle stakes are high, and so are concerns about side effects and safety. Recent studies report that Ozempic may cause severe conditions such as gastroparesis, bowel blockages, pancreatic and kidney injuries, and vision problems. Even hair loss is emerging as a potentially significant side effect, especially for women—according to recent findings, female users experienced about twice the rate of hair loss compared to those not using Ozempic.Because of these risks, there are currently over two thousand active lawsuits against Novo Nordisk and other GLP-1 manufacturers, with ongoing multidistrict litigation. These lawsuits allege that the companies did not give enough warning about the dangers, and some patients claim life-changing or life-threatening complications.Compounded GLP-1 drugs, made in pharmacies rather than by pharmaceutical companies, became popular when Ozempic was in short supply. However, the FDA warns that compounded drugs can be risky because they're not evaluated for safety or effectiveness. While the shortage has officially ended, compounded formulations remain in circulation.If you are considering Ozempic—whether as a pill, injection, or a compounded version—talk with your healthcare provider and review your health history, genetic background, and lifestyle goals. Widespread interest has led to changing availability, promising new forms, and more transparent labeling, especially after recent updates about kidney and pancreatic risks.To sum up, Ozempic continues to make waves as both a treatment for diabetes and a potent tool for weight loss. With fresh news about new pill forms, higher effective doses, genetic influences, and ongoing legal cases, it's important to stay informed and make choices based on both science and your personal health needs.Thanks for tuning in to Ozempic Weightloss Unlocked. Don't forget to subscribe to stay up to date on the latest developments. This has been a Quiet Please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Melt Away Fat! Never Diet Again!! The promises of “magic pills” that will lead to safe, effortless weight loss are everywhere. But while these mythical weight loss products may never exist…the FDA is getting ready to approve something extremely close. The news has been nearly impossible to miss…with a tidal wave of interest in medications that are revolutionizing an innovative approach to weight loss is swiftly evolving. Unlike past diet and weight loss trends, GLP-1 drugs are generating levels of enthusiasm that have rarely been seen. And honestly, there are few examples from history that have generated such impact. What once started as a lesser-known treatment (aiming to control blood glucose levels) of type-2 diabetics has turned Ozempic, Wegovy, Mounjaro, and Zepbound into household names, and brought us to the cusp of a health revolution. Furthermore, the next few days, months, and beyond, are shaping up to be a pivotal time for the GLP-1 landscape…mostly due to the FDA expectantly approving the first orally administered medication for chronic weight management (i.e. oral Wegovy semaglutide) sometime during this fourth quarter of 2025. Though, if this discovery has fueled an unprecedented surge in interest and demand for these current injectable peptides, why then are companies working so hard to make oral tablet forms of weight loss drugs that target the GLP-1 receptor? From a business perspective, there are some obvious advantages…such as oral tablet formulations tend to be cheaper and easier to manufacture and distribute than sterile injector pens. In fact, manufacturing complexity, both in terms of making the peptide active ingredients and producing the final injectors…significantly contributed to both Eli Lilly and Novo Nordisk struggling to supply surging demand for their products following approvals for weight loss indications. And from a patient perspective, oral weight loss pills are attractive for several reasons…most notably enhancing convenience for those who simply prefer pills to injections and making treatment accessible to those who are “extremely needle-phobic.” However, while tablet forms are generally more familiar and accessible to most individuals, the relative success of any oral drugs will likely depend on a combination of price, performance, and side-effect profiles. And although oral Wegovy is expected to be approved first, competition will quickly heat up from a myriad of biopharma companies, including Eli Lilly, Viking Therapeutics, Biomed, and Roche. In fact, Eli Lilly is expected to submit its application soon to the FDA for its once daily oral weight loss drug (with potential regulatory approval in 2026). Regardless, the demand for effective weight loss treatments is huge…and there's ample space in the market for a variety of complementary therapies. According to recent Goldman Sachs projections, the U.S. weight loss medication market will essentially triple to over $60 billion by 2030…with oral versions accounting for a quarter of that total market size. While oral weight loss drugs represent (in my opinion) one of the most significant new product cycles across the entire biopharma sector, there's no guarantee they make an immediate disruptive market impact or outcompete existing injectables long-term. And these will be margin accretive for the pharmaceutical industry's newest cash cow…even if this first wave isn't perfect, there will be a next wave of improvements, and then another new wave of improvements after that (if appropriate).

Morgan Stanley now holds the most pessimistic view of Novo Nordisk's (NVO) stock. It downgraded the company to underweight from equal weight and set a Street-low price target of $47. Marley Kayden talks about how the company's Alzheimer trials for one of its treatments played a key role in the downgrade. Prosper Trading Academy's Charles Moon goes against the tide and explains why he sees short-term potential through an example options trade.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Vi tager en status på Novo Nordisk, der er kommet i modvind blandt analytikerne, og aktien er nu faldet tilbage under kurs 400. Vi diskuterer også droner og kigger nærmere på det danske marked for droner, højteknologiske radar og antidronedroner. Det står nemlig ret klart, at vi har fremragende dronevirksomheder i f.eks. Aalborg, Allerød, Aarhus og København, der sagtens kunne have leveret dronebeskyttelse til danske lufthavne. Hvordan kan man investere i droner og forsvarsaktier, hvis man har et godt øje til industrien? Vi ser på mulighederne. Til sidst snakker vi om risikoen for en økonomisk nedlukning i USA, hvor politikerne stadig ikke har landet en aftale om det føderale budget. I studiet: Magnus Barsøe og Mikael Milhøj.See omnystudio.com/listener for privacy information.

Palm oil scandal, pharma tariffs, market jitters - what’s next for global investors? Hosted by Michelle Martin with Ryan Huang, we unpack Wilmar International’s corruption fallout, Donald Trump’s 100% pharma tariffs, and Chugai Pharmaceutical and Novo Nordisk’s market reaction. We explore the Buffett Indicator’s warning on U.S. equities, Nike’s upcoming earnings, and local market movers like Centurion Accommodation REIT, CapitaLand India Trust, and Jardine Matheson. Plus, our daily UP or DOWN verdict on Lululemon, Microsoft, and more. A fast-moving episode on scandals, stocks, and strategy.See omnystudio.com/listener for privacy information.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Hij is vaak voorspeld. Door autojournalisten, door analisten. Telkens wist Elon Musk hem te ontwijken, maar nu lijkt dat lastig. Techbedrijf Xiaomi, slechts een jaar bezig, zou dan toch echt dé Tesla-killer worden.De Chinese autobouwer wil showrooms openen in Europa en zelfs ook auto's willen bouwen op ons continent. Deze aflevering kijken we wat dat voor autobouwers (en Tesla in het specifiek) betekent. Ook duiken we in het aandeel van Xiaomi. Dat is in 12 maanden met bijna 200 procent gestegen.Hebben we het ook over Apple. Dat wil dat Brussel de regels aanpast. Volgens eigen zeggen is de wet digitale markten niet goed voor gebruikers, maar het lijkt er op dat Apple vooral zelf last heeft van de wet.Intel heeft op zijn beurt weer wat nodig van Apple. Geld en een samenwerking om precies te zijn. Rupsje Nooitgenoeg wil namelijk nog meer centjes bij (oud) klanten ophalen.Verder bespreken we het onderzoek dat Brussel doet naar SAP, een Amerikaans onderzoek naar Philips en hun concurrenten, TKH dat iets afsplitst (of toch niet) en je hoort meer over Trump die 'gesaboteerd' wordt. See omnystudio.com/listener for privacy information.

Sundhed er en samfundsmæssig megatrend, men investeringsmæssigt har det ikke været interessant i 2025 indtil videre. Sektoren halter godt og grundigt efter resten af markedet, og Millionærklubben undersøger i dagens program hvorfor. Vi diskuterer også om sektoren er en attraktiv investeringsmulighed lige nu, og så tager vi temperaturen på fedmemarkedet, Novo Nordisk og Eli Lilly efter sidste uges diabeteskonference i Wien. Med i studiet er aktiechef i HC Andersen Capital Michael Friis Jørgensen og adm. direktør i Global Health Invest Claus Johansen. Vært: Adam Geil See omnystudio.com/listener for privacy information.

...Novo Nordisk คือใคร? ...การสะดุดของบริษัทนี้บริษัทเดียว อาจสะเทือนทั้งประเทศ? ...ทำไมการสะดุดของบริษัทนี้ อาจทำให้เศรษฐกิจเดนมาร์กสั่นคลอน? เฟิร์น ศิรัถยา อิศรภักดี จะมาเล่าให้ฟังใน Wealth Story by UOB ทุกเรื่องที่ (ทำไม) เราต้องรู้? ทาง Wealth Me Up Channel #WealthMeUp #ให้เงินทำงาน #WealthStorybyUOB 

Fortsat stor usikkerhed efter droneflyvninger. Fyrings­runden i Novo er begyndt siger fagforeninger. Investorer i Ørsted jubler. Mette Frederiksen laver lille ministerrokade. Ingen garanti for flere rentesænkninger i USA, siger Powell. Trump kritiserer FN og kalder klimaforandringer "nonsens". Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Nando Sommerfeldt über die große Parkinson-Wette von Bayer, den BYD-Abschied von Warren Buffett und die unglaubliche Mag7-Bilanz. Außerdem geht es um Pfizer, Metsera, Eli Lilly, Novo Nordisk, Porsche Automobil Holding SE, Porsche AG, Volkswagen, Berkshire Hathaway, BYD, Taiwan Semiconductor, Amundi MSCI USA Daily (2x) Leveraged ETF (WKN: A0X8ZS), WisdomTree Nasdaq 100 3x Daily Leveraged ETP (WKN: A3GL7E), WisdomTree Dax 3x Daily Leveraged ETP (WKN: A1VBKS), Invesco Nasdaq 100 (WKN: 801498). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Dat ABN Amro een overnameprooi was, daar werd al langer over geroddeld. Maar het blijken de Belgen die er wel interesse in hebben. De Belgische concurrent KBC overweegt volgens Bloomberg een overname. Er is nog wel één discussiepunt binnen de Belgische bank: hoeveel hebben we ervoor over? Het onderzoek daarnaar zou nog in een vroeg stadium zijn, maar beleggers sorteren er wel alvast op voor. Of we er serieus rekening mee moeten houden dat ABN Amro binnenkort van onze AEX vertrekt, dat hoor je deze aflevering. Diezelfde AEX is sinds vandaag trouwens een stukje groter. Er zitten nu 30 bedrijven in, in plaats van 25. Al wordt er op die eerste dag van de uitbreiding alweer gespeculeerd hoe lang de zaken zo blijven, want op de aandelen Just Eat Takeaway en JDE Peet's staat alweer een 'verkocht'-bord. Wij speculeren lekker mee wie er dan vervolgens weer een plekje in de hoofdindex verdienen. En we vertellen je ook nog waarom Warren Buffet uit de Chinese autobouwer BYD stapt én wat hij eraan verdiend heeft. We onderzoeken hoe ver de bodem reikt voor bodemonderzoeker Fugro. En je hoort waarom een bedrijf dat nog helemaal niks verkoopt, toch ruim 60 procent hoger staat op de Nasdaq vandaag. See omnystudio.com/listener for privacy information.

In this episode, we dive into the realities of dealing with portfolio drawdowns as dividend growth investors. From personal examples to strategies for averaging down, price anchoring, and knowing when to hold or sell, we share how we manage the emotions that come with falling share prices.We also cover the latest news and dividend hikes, including:Novo Nordisk – promising results from its new oral weight-loss drugLondon Stock Exchange Group – stepping into blockchain with MicrosoftIntel & Nvidia – surprising partnerships in the chip industryTexas Instruments, Microsoft, W.P. Carey, and Philip Morris – dividend hike updatesPlus, we review Bradley's dividend portfolio and answer listener questions on hedging against USD, quick dividend stock screeners, reinvestment strategies, tax-efficient accounts, and more.

Summary del Show: • Wall Street sube con $SPX +0.2%, apoyado en expectativas de más recortes de tasas y el impulso de grandes tecnológicas. • Nvidia $NVDA invierte $500M en Wayve para acelerar la conducción autónoma en Reino Unido. • Novo Nordisk $NVO despide a su equipo de ventas en EE.UU. en reestructuración bajo nuevo CEO. • WeRide $WRD obtiene permiso federal en Bélgica para operar su Robobus autónomo de nivel 4.

A.M. Edition for Sept. 18. The entertainment giant is pulling ‘Jimmy Kimmel Live!' after Kimmel accused ‘MAGA-land' figures of exploiting Kirk's death, sparking outrage from conservatives. Plus, the WSJ's Peter Loftus explains how weight-loss pills are going to upend the market, as a Novo Nordisk trial shows the pill is just as effective as its Wegovy shot. And, royalty, lavish dinners and tech CEOs: Britain turns on the charm offensive as Donald Trump's state visit to the United Kingdom continues. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus: We're exclusively reporting that Pentagon lawyers are raising concerns over President Trump's strikes on alleged drug boats. And, Novo Nordisk says its daily WeGovy pill helps patients lose about as much weight as its weekly injection. Kate Bullivant hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Intel shares climb after Nvidia announces a $5B investment.  Positive trial results raise Novo Nordisk shares. Plus, inside ABC's suspension of "Jimmy Kimmel Live!".  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Summary del Show: • Wall Street sube tras el primer recorte de tasas de 2025 por parte de la Fed, aunque persiste incertidumbre sobre el ciclo de flexibilización. • Nvidia $NVDA e Intel $INTC anuncian un acuerdo histórico para codesarrollar chips y $NVDA invierte $5B en acciones de Intel. • Palantir $PLTR cierra un contrato por £1.5B con el Reino Unido, convirtiendo a Londres en su hub europeo de defensa. • Novo Nordisk $NVO gana impulso tras datos clínicos que muestran ventaja cardiovascular de Ozempic frente a Trulicity de Eli Lilly $LLY.

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Home-building slowed more than expected in August. And Eli Lilly says its investigational diabetes pill outperformed Novo Nordisk's oral semaglutide in a clinical trial. Zoe Kuhlkin hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Cognitive Behavioral Therapy (CBT) is a powerful, proven tool for weight management. Dr. Sandy Van joins us on the show and shares how to identify unhelpful thoughts, shift them to supportive ones, and build lasting healthy habits around eating, physical activity, and self-care.The medical information in this podcast is provided as an information resource only. It is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice and treatment.This episode was sponsored by Novo Nordisk. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.

Paul McCulley makes the case for a quarter-point cut at what he calls the "most fraught" FOMC meeting in the past 40 years. Eli Lilly and Novo Nordisk race for the next weight-loss blockbuster drug. Plus, Goldman upgrades a consumer staple.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Join experts in obesity, Robert Kushner, MD, Michael Knight, MD, and Amanda Velazquez, MD, as they discuss impactful communication for patients with obesity. Bob Kushner, MD  Amanda Velazquez, MB, DABOM Michael Knight, MD, MSHP, FACP, DABOM

A.M. Edition for Sept. 10. Russian drones went further into NATO-territory than ever before during the Ukraine war, with Polish Prime Minister Donald Tusk calling the attack a large-scale provocation. WSJ editor Dan Michaels details the allied response and what we know so far. Plus, weight-loss drug giant Novo Nordisk slashes thousands of jobs. And, WSJ's Hannah Erin Lang details Robinhood's plans to launch a social-media platform, in a bid to get traders off Reddit. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Scott Becker covers market gains, Oracle's AI cloud surge, Wall Street's outlook, Novo Nordisk job cuts, and Amazon's AI edge.

Plus: A federal judge blocks President Trump from removing Lisa Cook from the Federal Reserve Board. And, Ozempic-maker Novo Nordisk cuts 9,000 jobs as weigh-loss drug competition bites. Kate Bullivant hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today we feature Saxo equity strategist Ruben Dalfovo helping break down what is driving the moon-shot in Oracle shares after the company blew the doors off of expectations with forward cloud infrastructure bookings in its earnings call after the close yesterday. We also look at the Klarna IPO forthcoming today, Novo Nordisk shares rallying on the company's cost reductions, the latest in geopolitics, macro and currencies and much more. Hosting today's pod is Saxo Global Head of Macro Strategy John J. Hardy. Links discussed on the podcast and our Chart of the Day can be found on the John J. Hardy substack (with a one- to two-hour delay from the time of the podcast release). Read daily in-depth market updates from the Saxo Market Call and the Saxo Strategy Team here. Please reach out to us at marketcall@saxobank.com for feedback and questions. Click here to open an account with Saxo. Intro and outro music by AShamaluevMusic

This week's Market Mondays is packed with high-level investing questions and timely market insights. We break down which five companies could thrive under a Trump administration, discuss whether Nvidia has a revenue concentration problem, and share advice for investors earning $50K–$100K per year on how to balance stocks, bonds, and real estate. We also dive into how to calculate intrinsic value—Ben Graham style, Warren Buffett style, or your own strategy—and what to actually do when your 5–10 year holding period is up.We also explore September 2025 market outlooks, Morgan Stanley's latest stock picks, and Alibaba's surprising surge after reports it may challenge Nvidia in the AI chip space. From fixed income products like MSTY and NVDY to the crypto markets hovering at key Fibonacci levels, we break down what's holding Bitcoin and ETH back, and how investors should be positioning in a historically tricky month. Plus, we play a round of “Don't Love, Marry, Kill” with Charter Communications, Hormel Foods, and Keurig Dr Pepper.Finally, we dig into the brewing legal storm around Novo Nordisk and Eli Lilly, facing over 2,000 lawsuits tied to Ozempic and similar drugs, with potential liability estimated in the billions. Is this the “death of Novo Nordisk,” or just another chapter in the evolving GLP-1 drug story? Tune in for sharp analysis, real strategies, and answers to the questions you've been asking all week.#MarketMondays #Investing #Stocks #Crypto #AI #Trump #Nvidia #Ozempic #WealthBuilding #FinancialLiteracyOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy